A critical evaluation of crizanlizumab for the treatment of sickle cell disease.

Nabin Raj KarkiKatherine SaundersAbdullah Kutlar

Published in: Expert review of hematology (2021)

Crizanlizumab holds great promise in modulating the natural history of sickle cell disease and may have pleotropic effects. Studies are ongoing to define its role in preventing other sickle cell-related complications, non-sickle cell inflammatory states, and thrombotic disorders.

Keyphrases

sickle cell disease
signaling pathway
risk factors
case control
machine learning
combination therapy
smoking cessation